Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleukin-12

Clinical and Experimental Metastasis

Volumn 17, Issue 1, 1999, Pages 63-70

  Shrayer, David P ^a,e   Cole, Bernard ^b   Hearing, Vincent J ^c   Wolf, Stanley F ^d   Wanebo, Harold J ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MS 35 1127   (United States)

^e ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

IL 12; Irradiated melanoma vaccine; Lymphokines; Melanoma; Metastasis

Indexed keywords

CANCER ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA ANTIGEN; MELANOMA VACCINE; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IRRADIATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN;

ANIMALS; CANCER VACCINES; IMMUNOTHERAPY; INTERLEUKIN-12; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SURVIVAL RATE;

EID: 0033017239     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Stern AS, Podlaski FJ, Hulmes JD et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-12.
2. Wolf SF, Temple PA, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-81.
3. Schoenhault DS, Chua AO, Wolitzky AG et al. Cloning and expression of murine IL-12. J Immunol 1990; 148: 3433-40.
4. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-30.
5. Tahara H, Zeh III HJ, Storkus WJ et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-9.
6. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153: 1697-1706.
7. Hill LL, Perussia B, McCue PA, Korngold R. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res 1994; 54: 763-70.
8. Mu J, Zou J-P, Yamamoto N et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995; 55: 4404-8.
9. Coughlin CM, Wysocka, Kurzawa HL et al. B7-1 and inteleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995; 55: 4980-7.
10. Murphy EE, Terres G, Macatonia SE et al. B7 and interleukin 12 cooperate for proliferation and interferon-γ production by mouse clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180: 223-31.
11. Shrayer D, Bogaars H, Hearing VJ et al. Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine. Cancer Immunol Immunother 1995; 40: 277-82.
12. Noguchi Y, Richards EC, Chen Y-T, Old L. Influence of interleukin 12 on p53 peptide vaccination against established meth A sarcoma. Proc Natl Acad Sci USA 1995; 92: 2219-23.
13. Meko JB, Yim JH, Tsung K, Norton JA, High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995; 55: 4765-70.
14. Tahara H, Zitvogel L, Storkus WJ et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-74.
15. Vagliani M, Rodolfo M, Cavallo F et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 1996; 56: 467-70.
16. Shrayer DP, Koness J, Kouttab N et al. Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model. J Surg Oncol 1993; 52: 142-9.
17. Shrayer DP, Koness J, Kouttab N et al. Anti-tumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int J Oncol 1994; 4: 1121-7.
18. Hearing VJ, Gersten DM, Shrayer D, Law LW. Novel experimental approaches to melanoma diagnosis and therapy. J Dermatol 1994; 21 (11): 860-9.
19. Shrayer DP, Koness J, Maizel A, Wanebo H. Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA) of murine melanoma. Melanoma Res 1992; 2: 47-56.
20. Shrayer DP, Kouttab N, Maizel A et al. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int J Cancer 1993; 53: 696-702.
21. Wiggington JM, Kuhns DB, Back TC et al. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity. Cancer Res 1996; 56: 1131-6.
22. Wynn TA, Jankovic D, Hieny S et al. IL-12 exacerbates rather than suppresses T helper 2-dependent pathology in the absence of endogenous INF-γ. J Immunol 1995; 154: 3999-4009.
23. Bliss J, Van Clive V, Murray K et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol 1996; 156: 887-94.
24. Shrayer DP, Bogaars H, Wolf JF, Wanebo HJ. Capacity of murine IL-12 to inhibit the development of implanted primary melanoma tumors and to prevent lung metastases in the melanoma challenged mice. J Exper Therap Oncol 1999 (in press).
25. Shrayer DP, Bogaars H, Hearing VJ, Wanebo HJ. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. J Exp Ther Oncol 1996; 1: 126-33.
26. Shrayer DP, Gersten DM, Koness J et al. B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens. Pigment Cell Res 1997; 5: 107-12.
27. Shrayer DP, Park C-H. Kouttab N et al. Intrasplenic vaccination against experimental melanoma. Int J Oncol 1996; 9: 1123-9.
28. Gersten DM, Marchalonis JJ. Demonstration and isolation of murine melanoma-associated antigenic surface proteins. Biochem Biophys Res Commun 1979; 90: 1015-24.
29. Hearing VJ, Gersten DM, Montague PM et al. Murine melanoma-specific tumor rejection activity elicited by a purified melanoma-associated antigen. J Immunol 1986; 137: 1, 379-84.
30. Fidler IJ. Selection of successive tumor lines for metastasis. Nature (New Biol) 1973; 242: 148-9.
31. Fidler IJ Gersten DM, Riggs CW. Relationship of host immune status to tumor cell arrest, distribution and survival in experimental metastasis. Cancer 1977; 40: 46-55.
32. Ariel IM. Malignant Melanoma. New York: Appleton-Century-Crofts 1981.
33. Shrayer DP, Koness J, Bogaars H et al. Interleukin-2, natural killer cells and antimelanoma antibodies after immunization of mice with formalinized extracellular antigens (FECAs) of B16-F10 melanoma. 3rd Annual Meeting ESPCR, Amsterdam 1991; 69: 8-11.
34. Gersten DM, Hearing VJ, Marchalonis JJ. Characterization of immunologically significant unique B16 melanoma proteins produced in vivo and in vitro. Proc Natl Acad Sci USA 1981; 78: 5109-12.
35. Gersten DM and Hearing, VJ. Antigens of murine melanoma and their cross-reactivity. Pathobiology 1992; 60: 49-56.
36. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
37. Miller MA, Skeen MJ, Ziegler HK. Nonviable bacterial antigens administrated with IL-12 generate antigen-specific T cell responses and protective immunity against Listeri monocytogenes. J Immunol 1995; 155: 4817-28.
38. Mountford AP, Anderson S, Wilson RA. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J Immunol 1996; 156: 4739-45.
39. Kubin M, Kamon M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180: 211-22.
40. Rao B, Chamberlain RS, Bronte V et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines. J Immunol 1996; 156: 3357-65.
41. Muller G, Saloga J, Germann T et al. Identification and induction of human keratinocyte-derived IL-12. J Clin Invest 1994; 94: 1799-1805.
42. Neurath MF, Fuss I, Kelsall BL et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-90.
43. Wilkinson VL, Warrier RR, Truitt TP et al. Characterization of anti-mouse IL-12 monoclonal antibodies and measurement of mouse IL-12 by ELISA. J Immunol Meth 1996; 189: 15-24.
44. Jones BM. Effect of neutralizing anti-cytokine antibodies on in vitro activation pf B-cells. Interleukin IL-12 is required by B1a but not B2 cells. Scand J Immunol 1996; 43: 64-72.
45. Obana S, Miyazawa H, Tamura T et al. Induction of anti-tumor immunity by mouse tumor cells transfected with mouse interleukin-12 gene. Jpn J Med Sci Biol 1995; 48: 221-36.
46. Schadendorrf D, Czametzki BM, Wittig B. Interleukin 7, interleukin 12, and GM-CSF gene transfer. J Mol Med 1995; 73: 473-7.
47. Rakhmilevich AL, Turner J, Ford MJ et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291-6.
48. Fujiwara H, Hamaoka T. Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 1996; 38 (Suppl): 822-6.